<DOC>
	<DOCNO>NCT01121224</DOCNO>
	<brief_summary>Patients undergone coronary bypass surgery vein remove leg implant chest `` bypass '' blockage coronary artery . These vein call saphenous vein graft SVGs . SVGs often develop blockage cause chest pain heart attack . SVG blockage open use small balloon stent ( metal coil keep artery open ) . Two type stent currently use : bare metal stent ( BMS ) drug-eluting stent ( DES ) . Both BMS DES make metal . DES also coat drug release wall blood vessel prevent scar tissue form re-narrowing vessel . Both stent advantage disadvantage : DES require take special blood thinner ( call thienopyridines , clopidogrel prasugrel ) long bare metal stent could bleed also less likely renarrow . Both BMS DES routinely use SVGs , know one good . Neither bare metal ( except outdated model ) drug-eluting stent FDA approve use SVGs . The purpose CSP # 571 compare outcome DES vs. BMS use SVGs . In CSP # 571 patient need stenting SVG blockage randomize receive DES BMS 1:1 ratio . Per standard practice , patient receive 12 month open label thienopyridine acute coronary syndrome ( ACS ) , another clinical reason need medication . Patients without ACS receive DES also need take 12 month thienopyridine whether study , non-ACS patient receive BMS . In order make sure patient know stent receive , non-ACS patient receive BMS receive 1 month open label thienopyridine follow 11 month blind placebo , receive DES receive 1 month open label thienopyridine follow 11 month blind clopidogrel , thienopyridine . All study patient follow clinic least 1 year stenting procedure see difference rate cardiac death , heart attack , procedure require order increase flow blood heart BMS DES group .</brief_summary>
	<brief_title>Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty</brief_title>
	<detailed_description>VA Cooperative Studies Program # 571 design prospectively evaluate efficacy drug-eluting stent ( DES ) reduce aortocoronary saphenous vein bypass graft ( SVG ) failure compare bare metal stent ( BMS ) patient undergo stenting de novo SVG lesion . SVGs often develop luminal stenosis commonly treat stent implantation . Approximately 60,000-100,000 percutaneous SVG intervention perform annually USA . Two type coronary stent currently available : bare metal stent drug elute stent . Bare metal stent standard care percutaneous treatment SVG lesion , limited high rate in-stent restenosis ( high 51 % 12 month ) often leading repeat percutaneous surgical SVG treatment . Drug-eluting stent show significantly reduce in-stent restenosis need repeat target vessel lesion revascularization native coronary artery , yet efficacy SVGs well study , conflict result various small study . The propose Cooperative Studies Program study first large prospective , randomize , multicenter , blind clinical trial compare DES BMS SVG lesion . It provide critical knowledge assist cardiac interventionalist select optimum stent type challenge lesion . Patients undergo clinically-indicated stenting de novo SVG lesion randomize 1:1 ratio DES BMS . To ensure blind type stent use , patient present acute coronary syndrome require 12 month dual antiplatelet therapy , receive DES receive 11 month clopidogrel receive BMS receive 11 month match placebo . After stenting , patient follow clinically minimum one year determine 12-month incidence target vessel failure ( TVF , primary study endpoint ) . TVF define composite cardiac death , target vessel myocardial infarction target vessel revascularization , primary clinical endpoint use FDA-approved DES pivotal trial . Coronary angiography intervention follow-up perform clinically-indicated ( mandatory angiographic follow-up ) . Secondary endpoint include : 1 ) clinical outcome TVF ( procedural success ; post-procedural myocardial infarction ; post-procedural bleeding ; cause death cardiac death ; follow-up myocardial infarction ; stent thrombosis ; target lesion revascularization ; target vessel revascularization ; non-target vessel revascularization ; composite endpoint death , MI , target vessel revascularization ( patient-oriented composite endpoint accord FDA guidance document DES study ) ; composite endpoint cardiac death , target vessel myocardial infarction , target lesion revascularization ( device-oriented composite endpoint target lesion failure ) ; stroke ) ; 2 ) incremental cost-effectiveness DES relative BMS . A tertiary endpoint in-stent neointima proliferation measure intravascular ultrasonography . Based published study , investigator estimate 12-month TVF rate BMS arm 30 % . The investigator hypothesize DES reduce TVF 18 % ( 40 % relative reduction ) . Assuming two-year accrual one interim assessment , total sample size 520 patient need detect difference 90 % power , use two-sided 5 % significance level . Assuming intake rate 1 patient per month per VAMC , investigator need 22 participate site . However , investigator begin study 25 site protect site dropout rate 10 % . Percutaneous treatment SVG lesion particular importance VA system many Veterans undergone continue undergo coronary artery bypass graft surgery . Every year , approximately 12-15 % percutaneous coronary intervention perform within VA system perform SVGs , cost approximately $ 15,000- $ 20,000 per procedure ; DES currently use approximately half SVG intervention . Because ( ) high prevalence high cost SVG stenting , ( b ) DES cost two- three- fold BMS often require prolonged ( 12 month ) thienopyridine administration prevent late stent thrombosis , ( c ) DES may increase risk late late stent thrombosis , catastrophic complication high mortality , propose study considerable impact clinical practice SVG lesion stenting , patient satisfaction , financial burden health care system ( within outside VA ) , regardless whether result positive ( DES offer significantly superior health benefit patient BMS ) , negative ( DES offer significantly superior health benefit patient BMS ) . Due decrease profit increase competition , DES manufacturer plan ever fund SVG DES study . The VA system Cooperative Studies Program uniquely suit conduct propose study .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Age 18 year Need percutaneous coronary intervention 5099 % de novo SVG lesion 2.25 4.5 mm diameter consider cause clinical functional ischemia Intent use distal embolic protection device Agrees participate take prescribed medication instruct Has provide inform consent agree participate Planned noncardiac surgery within follow 12 month Presentation STsegment elevation acute myocardial infarction Target SVG last remaining vessel `` leave main '' equivalent Any previous percutaneous treatment target lesion ( balloon angioplasty , stent , intravascular brachytherapy etc ) Any previous percutaneous treatment target vessel ( lesion different target lesion ) within prior 12 month Hemorrhagic diatheses , refusal receive blood transfusion Warfarin administration require next 12 month patient consider high risk bleed triple anticoagulation/antiplatelet therapy Recent positive pregnancy test , breastfeeding , possibility future pregnancy ( define prior hysterectomy &lt; 5 year elapse since last menstrual period ) Coexisting condition limit life expectancy le 12 month History allergic reaction significant sensitivity drug sirolimus , paclitaxel , zotarolimus , everolimus include various DES . History allergic reaction significant sensitivity L605 cobalt chromium alloy ( cobalt , silicon , chromium , tungsten , manganese , iron , nickel ) , F562 cobalt chromium alloy ( cobalt , chromium , nickel ) , 316L surgical stainless steel ( iron , chromium , nickel , molybdenum ) , MP35N cobaltbased alloy ( cobalt , nickel , chromium , molybdenum , titanium , iron , silicon , manganese ) , component platinum chromium alloy stent . Allergy clopidogrel patient present acute coronary syndrome ( ACS ) , ACS define cardiac ischemic symptom occur rest 1 follow 3 criterion : electrocardiographic change suggestive ischemia ( STsegment elevation depression 1 mm 2 contiguous lead , new leave bundle branch block , posterior myocardial infarction ) ; positive biomarker indicate myocardial necrosis ( troponin I T CKMB great upper limit normal ) ; coronary revascularization perform hospitalization trigger cardiac ischemic symptom Participating another interventional randomize trial ( require condition CSP study ) dual enrollment DIVA approve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Saphenous vein graft</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
	<keyword>Stents</keyword>
</DOC>